Moderna (NASDAQ:MRNA) Stock Price Crosses Below 50-Day Moving Average After Insider Selling

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) crossed below its 50-day moving average during trading on Wednesday after an insider sold shares in the company. The stock has a 50-day moving average of $205.61 and traded as low as $196.52. Moderna shares last traded at $196.79, with a volume of 6,954,950 shares traded.

Specifically, President Stephen Hoge sold 39,160 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $219.66, for a total value of $8,601,885.60. Following the transaction, the president owned 1,673,858 shares of the company’s stock, valued at $367,679,648.28. This represents a 2.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,215 shares of Moderna stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $211.61, for a total transaction of $8,298,286.15. Following the sale, the president directly owned 1,311,095 shares of the company’s stock, valued at approximately $277,440,812.95. This trade represents a 2.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

Several equities analysts recently issued reports on MRNA shares. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Singular Research upgraded Moderna to a “hold” rating in a report on Wednesday, September 23rd. Royal Bank Of Canada reiterated a “sector perform” rating and set a $130.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Friday, August 28th. Finally, Bradesco Corretora upgraded shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $120.25.

Check Out Our Latest Analysis on Moderna

Key Stories Impacting Moderna

These are some of the MRNA stories that stood out recently:

  • Positive Sentiment: Moderna’s Phase 3 adjuvant melanoma results were described as clinical proof of concept, strengthening the outlook for its immuno-oncology program, according to Morgan Stanley. Read article
  • Neutral Sentiment: Morgan Stanley raised its price target from $95 to $200 but kept an “equal weight” rating, signaling a more constructive target without a bullish recommendation. Read article
  • Negative Sentiment: Recent coverage says the shares have extended a losing streak after a major year-to-date rally, raising concerns about momentum and whether expectations already reflect a recovery. Read article Read analysis

Moderna Trading Down 4.8%

The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The business has a fifty day moving average of $205.61 and a 200-day moving average of $98.82. The stock has a market capitalization of $79.63 billion, a price-to-earnings ratio of -27.72 and a beta of 1.16.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s revenue was up 29.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.51) EPS. On average, equities analysts anticipate that Moderna, Inc. will post -5.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Moderna in the 2nd quarter worth about $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna during the 2nd quarter valued at $564,272,000. Merck & Co. Inc. bought a new position in shares of Moderna during the 2nd quarter valued at $161,642,545. Bamco Inc. NY acquired a new stake in shares of Moderna in the 2nd quarter valued at $139,317,000. Finally, Bank of New York Mellon Corp bought a new position in Moderna during the second quarter valued at about $119,168,000. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories